17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery
A Cancer Research UK Phase I Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of 17-Dimethylaminoethyl-amino-17-Demethoxygeldanamycin (17-DMAG) Given as a Once Weekly Infusion in Patients With Advanced Solid Tumors
Sponsor: Institute of Cancer Research, United Kingdom
A PHASE1 clinical study on Unspecified Adult Solid Tumor, Protocol Specific, this trial is ongoing. The trial is conducted by Institute of Cancer Research, United Kingdom and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE1
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institute of Cancer Research, United Kingdom
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .